Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utomilumab with Trastuzumab or Ado-Trastuzumab Emtansine in HER2+ Advanced Breast Cancer
NCT03364348Phase 1Completed
- Start
- Oct 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of utomilumab in breast cancer (4 cohorts). Primary endpoint: Dose-limiting Toxicities at 6 weeks. Started Oct 2017; status: completed.
02
Drugs
utomilumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03364348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03364348.